Skip to main content

ACTH 1-39

No sources yet

An index of captured practitioner sources, not a completed evidence summary. Unchecked figures and empty sections are omitted. See the library review status.

Source summary generated November 6, 2026; this date does not indicate completed review.

HormonesAliases: ACTH, Corticotropin, adrenocorticotropic hormone
Track your own protocol free →

Quotes from three independent practitioners, with their sources. Research context only.

What it is and how it works

From the published literature on ACTH 1-39; the papers are listed at the end. Research summary, not a recommendation.

What it is

ACTH 1-39 (adrenocorticotropic hormone, also called corticotropin) is a natural peptide hormone of 39 amino acids made by the pituitary gland at the base of the brain, cut from a larger precursor protein called pro-opiomelanocortin. The approved medicine built on it is repository corticotropin injection (Acthar Gel), first approved in 1952, which the FDA label describes as a naturally sourced mixture made from pig pituitary extract whose major component is a modified porcine ACTH (1-39), held in a slow-release gel. A shorter synthetic fragment, cosyntropin (ACTH 1-24), is used mainly as a diagnostic test of adrenal function rather than as a treatment.

How it works

ACTH binds the melanocortin 2 receptor (MC2R, a receptor on the cells of the adrenal cortex, the outer layer of the adrenal glands), which signals those cells to make and release cortisol, the body's main stress and anti-inflammatory steroid hormone. The diagnostic stimulation test relies on this: cosyntropin is given and the rise in blood cortisol shows whether the adrenal glands can respond. ACTH also binds other members of the melanocortin receptor family (receptors found on immune cells, skin pigment cells, the brain and other tissues), and reviews describe anti-inflammatory effects on immune cells that do not depend on cortisol. Because much of its effect still runs through cortisol, its side effects largely resemble those of corticosteroid medicines.

What it has been studied for

  • Infantile spasms, a severe seizure disorder of infancy (randomized trials, summarized in a 2022 scoping review)
  • Relapses of multiple sclerosis (randomized trials)
  • Rheumatoid arthritis and other inflammatory conditions on the FDA label
  • Diagnosis of adrenal insufficiency with the cosyntropin (ACTH 1-24) stimulation test
  • Cortisol-independent anti-inflammatory actions through melanocortin receptors (reviews of lab and clinical work)

Strength of the evidence

Approved drugRepository corticotropin injection has been FDA approved since 1952 for infantile spasms, multiple sclerosis relapses and a list of inflammatory conditions, and cosyntropin is approved for adrenal testing, although a 2022 review found the controlled evidence for most labelled uses to be thin.

What the literature reports on safety

The FDA label for Acthar Gel lists corticosteroid-like risks: infections, Cushing's syndrome (effects of excess cortisol) and adrenal insufficiency when it is stopped, raised blood pressure with salt and water retention and low potassium; in infants treated for infantile spasms the most common reactions were infections, convulsions, high blood pressure, irritability and fever. The label contraindicates it for intravenous use, in infants with suspected congenital infections, with live vaccines during immunosuppressive treatment, and in people with scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, peptic ulcer, congestive heart failure, uncontrolled hypertension, adrenal disorders or sensitivity to pig proteins. A 2022 scoping review in JAMA Internal Medicine noted that the product's approval predated modern FDA review standards and that blinded trials showed similar or more adverse effects than corticosteroids.

Key papers

  1. Characterization of the Clinical Evidence Supporting Repository Corticotropin Injection for FDA-Approved Indications: A Scoping Review. (opens in a new tab)

    Review · Tran KA, Harrod C, et al. · JAMA Internal Medicine (2022) · PMID 34902005

    Across 41 studies with 2235 participants, few randomized trials supported a benefit for most FDA-approved uses, and most trials found corticotropin no better than corticosteroids for multiple sclerosis relapses or infantile spasms.

  2. ACTH: The forgotten therapy. (opens in a new tab)

    Review · Montero-Melendez T · Seminars in Immunology (2015) · PMID 25726511

    Reviewed evidence that ACTH acts not only by inducing cortisol but also directly on melanocortin receptors on immune cells, and proposed melanocortin drugs without steroid-producing effects as a route to fewer side effects.

  3. Pitfalls in the interpretation of the cosyntropin stimulation test for the diagnosis of adrenal insufficiency. (opens in a new tab)

    Review · Burgos N, Ghayee HK, Singh-Ospina N · Current Opinion in Endocrinology, Diabetes, and Obesity (2019) · PMID 30855285

    Summarized how the ACTH stimulation test is used when baseline cortisol is inconclusive, and how time of day, assay type and sample source affect its accuracy.

  4. Adrenocorticotropic hormone versus methylprednisolone added to interferon beta in patients with multiple sclerosis experiencing breakthrough disease: a randomized, rater-blinded trial. (opens in a new tab)

    Randomized trial · Berkovich R, Bakshi R, et al. · Therapeutic Advances in Neurological Disorders (2017) · PMID 28450891

    In a small pilot trial of 23 patients, monthly ACTH gel added to interferon beta was followed by fewer relapses than intravenous methylprednisolone, with no significant differences in disability, quality-of-life, bone density or MRI measures.

  5. The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial. (opens in a new tab)

    Randomized trial · Lux AL, Edwards SW, et al. · Lancet Neurology (2005) · PMID 16239177

    Among 107 infants randomized to hormone treatment or vigabatrin, hormone treatment controlled spasms better at first, spasm freedom was similar by 12 to 14 months, and development scores were higher with hormone treatment in infants with no identified underlying cause.

  6. Safety of repository corticotropin injection as an adjunctive therapy for the treatment of rheumatoid arthritis. (opens in a new tab)

    Review · Fleischmann R, Furst DE · Expert Opinion on Drug Safety (2020) · PMID 32497440

    Compared adverse events from a rheumatoid arthritis trial of add-on corticotropin with published trials of standard drugs plus steroids and found no clinically significant differences in short-term safety.

Sources checked: PubMed (E-utilities esummary and abstracts on every PMID), FDA label for Acthar Gel (accessdata.fda.gov, 2021 label 008372s071), written 2026-11-06.

No sources yet

None of the three teachers' sources we have indexed discuss ACTH 1-39 yet. This page will fill in as sources are added.

Deeper guided audio lives on What Am I Appreciating Now (leaves this site, opens in a new tab). What Am I Appreciating Now is a separate site run by the same operator; it sells meditation and hypnosis sessions.

Disclaimer: for research purposes only

All content on this page is for research and educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any peptide or hormone protocol. You take responsibility for your own protocol.If your path includes peptides, you buy them yourself from an independent licensed provider through a member co-op; we take nothing. How independent access works.

ACTH 1-39 — Hunter, Taylor, Bachmeyer | Reset Biology